Company History

Dermatology company Galderma’s detailed timeline:

2014

Foundation of Nestlé Skin Health. Galderma is now fully-owned by Nestlé.
Galderma enters into an agreement with Valeant, through which Galderma will gain full rights to commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada.

2013

Acquisition of Swiss company Spirig Pharma AG, manufacturer of Daylong & Excipial.
FDA approval of Mirvaso for the treatment of erythema associated with rosacea.

2012

Galderma defines its new 3-business-strategy and a new ambition statement.
Opening of a new affiliate in China.Cetaphil Dermacontrol is launched in 6 countries.

Inauguration of the new research and preclinical development building in Sophia Antipolis, France.
Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the United-States and acquisition of Tri-Luma.

2003

Launch of Metvix in Germany and the UK and Clobex Lotion (psoriasis) in the US.
Restylane is approved in the US.

Acquisition of Loceryl (fungal nail infections), developed by F. Hoffmann-La Roche Ltd, together with the Scandinavian dermatology portfolio developed by Nycomed.

1998

Inauguration of a new R&D facility in Princeton, New Jersey, USA.
Acquisition in Brazil of Darrow’s dermatology portfolio.

1997

Acquisition of Basotherm, a subsidiary of Boehringer.

1996

Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant. Restylane is approved for sales in Europe, for filling out of wrinkles and lip augmentation.